What is MRVI (MRVI) stock price today?

MRVI (MRVI) is currently trading at $6.90, up 3.06% today.

What is MRVI P/E ratio?

MRVI's P/E ratio is -4.48. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is MRVI return on equity (ROE)?

MRVI's return on equity (ROE) is -61.79%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is MRVI's market cap?

MRVI has a market capitalization of $1.90B.

NMS · Biotechnology

MRVI (MRVI) Stock

$6.90 +3.06% NMS: MRVI Healthcare

Valuation

Metric	Value
Price	$6.90
Market Cap	$1.90B
P/E Ratio	-4.48
P/B Ratio	5.32
P/S Ratio	5.50
EPS (TTM)	$-0.91
52-Week High	$7.20
52-Week Low	$1.99
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-61.79%
ROA	-16.99%
ROCE	-1.88%
Gross Margin	-3.23%
Operating Margin	-3.76%
Net Margin	-51.07%
Debt/Equity	0.17
Current Ratio	6.58

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$799.0M	$883.0M	$289.0M	$259.0M	$186.0M
Operating Profit	$555.0M	$574.0M	$-32.0M	$-236.0M	$-7.0M
Net Profit	$182.0M	$220.0M	$-119.0M	$-145.0M	$-131.0M
EPS	$1.56	$1.67	$-0.90	$-1.05	$-0.91
Op Margin	69.4%	65.0%	-10.9%	-90.9%	-3.6%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$1.9B	$2.3B	$1.5B	$1.0B	$771.0M
Total Liabilities	$1.4B	$1.4B	$698.0M	$431.0M	$398.0M
Cash	$551.0M	$632.0M	$575.0M	$322.0M	$217.0M
Borrowings	$575.0M	$585.0M	$611.0M	$377.0M	$36.0M

Latest News

Maravai Lifesciences Unit TriLink Opens Enzyme Manufacturing Facility in Florida MT Newswires · Jun 16, 2026 TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale Business Wire · Jun 16, 2026 Maravai Lifesciences Holdings Insider Sold Shares Worth $254,000, According to a Recent SEC Filing MT Newswires · Jun 10, 2026 This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio Insider Monkey · Jun 7, 2026 Maravai LifeSciences Refinances Credit Agreement, Extends Maturity to 2032 MT Newswires · Jun 3, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$369.0M	$536.0M	$126.0M	$7.0M	$-58.0M
Investing Cash Flow	$91.0M	$-285.0M	$-188.0M	$-54.0M	$-45.0M
Financing Cash Flow	$-155.0M	$-184.0M	$-55.0M	$-2.0M	$-11.0M
Net Cash Flow	$315.0M	$81.0M	$-57.0M	$-253.0M	$-106.0M
Free Cash Flow	$354.0M	$519.0M	$61.0M	$-22.0M	$-71.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	17.52
FCF Yield	-4.60%
Quick Ratio	4.96
Interest Coverage	-0.26
Return 1Y	180.63%
Return 3Y	-43.20%
Return 5Y	-83.10%

Ownership

Insiders Held13.80%

Institutions Held88.62%

Institutions Float Held102.81%

Institutional Holder	Shares	Report Date
GTCR, LLC	20,150,005	2026-03-31
Braidwell LP	10,240,164	2026-03-31
Blackrock Inc.	9,345,268	2026-03-31
12 West Capital Management Lp	7,260,195	2026-03-31
Mackenzie Financial Corporation	6,306,425	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BCAX	$27.81	+2.92%	-7.37	$1.52B	0.00%
DNA	$8.07	-0.19%	-1.30	$527.50M	0.00%
IOVA	$4.36	+1.04%	-12.36	$1.95B	0.00%
KURA	$9.57	+3.13%	-2.90	$849.57M	0.00%
LENZ	$5.05	+1.10%	-3.18	$158.34M	0.00%

About MRVI

MRVI is led by CEO Bernd Brust, employs 570 people, headquartered in US, publicly traded since 2020.

MRVI stock trades at $6.90 with a market capitalization of $1.90B. The stock is valued at a price-to-earnings (P/E) ratio of -4.48, price-to-book of 5.32, price-to-sales of 5.50. Over the past 52 weeks the stock has ranged between $1.99 and $7.20, and currently trades 4.2% below its 52-week high.

On profitability, MRVI generates a return on equity (ROE) of -61.79%, return on capital employed of -1.88%, an operating margin of -3.76%, a net profit margin of -51.07%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides